Enhancer rewiring in tumors: an opportunity for therapeutic intervention
- PMID: 33934105
- DOI: 10.1038/s41388-021-01793-7
Enhancer rewiring in tumors: an opportunity for therapeutic intervention
Abstract
Enhancers are cis-regulatory sequences that fine-tune expression of their target genes in a spatiotemporal manner. They are recognized by sequence-specific transcription factors, which in turn recruit transcriptional coactivators that facilitate transcription by promoting assembly and activation of the basal transcriptional machinery. Their functional importance is underscored by the fact that they are often the target of genetic and nongenetic events in human disease that disrupt their sequence, interactome, activation potential, and/or chromatin environment. Dysregulation of transcription and addiction to transcriptional effectors that interact with and modulate enhancer activity are common features of cancer cells and are amenable to therapeutic intervention. Here, we discuss the current knowledge on enhancer biology, the broad spectrum of mechanisms that lead to their malfunction in tumor cells, and recent progress in developing drugs that efficaciously target their dependencies.
Similar articles
-
Transcriptional dysregulation by aberrant enhancer activation and rewiring in cancer.Cancer Sci. 2021 Jun;112(6):2081-2088. doi: 10.1111/cas.14884. Epub 2021 May 1. Cancer Sci. 2021. PMID: 33728716 Free PMC article. Review.
-
Identification of activated enhancers and linked transcription factors in breast, prostate, and kidney tumors by tracing enhancer networks using epigenetic traits.Epigenetics Chromatin. 2016 Nov 9;9:50. doi: 10.1186/s13072-016-0102-4. eCollection 2016. Epigenetics Chromatin. 2016. PMID: 27833659 Free PMC article.
-
Enhancer RNAs in cancer: regulation, mechanisms and therapeutic potential.RNA Biol. 2020 Nov;17(11):1550-1559. doi: 10.1080/15476286.2020.1712895. Epub 2020 Jan 19. RNA Biol. 2020. PMID: 31916476 Free PMC article. Review.
-
The molecular understanding of super-enhancer dysregulation in cancer.Nagoya J Med Sci. 2022 May;84(2):216-229. doi: 10.18999/nagjms.84.2.216. Nagoya J Med Sci. 2022. PMID: 35967935 Free PMC article. Review.
-
Enhancer malfunction in cancer.Mol Cell. 2014 Mar 20;53(6):859-66. doi: 10.1016/j.molcel.2014.02.033. Mol Cell. 2014. PMID: 24656127 Free PMC article. Review.
Cited by
-
Epigenetic reprogramming of a distal developmental enhancer cluster drives SOX2 overexpression in breast and lung adenocarcinoma.Nucleic Acids Res. 2023 Oct 27;51(19):10109-10131. doi: 10.1093/nar/gkad734. Nucleic Acids Res. 2023. PMID: 37738673 Free PMC article.
-
Genetic coupling of enhancer activity and connectivity in gene expression control.Nat Commun. 2025 Jan 27;16(1):970. doi: 10.1038/s41467-025-55900-3. Nat Commun. 2025. PMID: 39870618 Free PMC article.
-
Transcriptional enhancers and their communication with gene promoters.Cell Mol Life Sci. 2021 Oct;78(19-20):6453-6485. doi: 10.1007/s00018-021-03903-w. Epub 2021 Aug 19. Cell Mol Life Sci. 2021. PMID: 34414474 Free PMC article. Review.
-
Enhancing B-Cell Malignancies-On Repurposing Enhancer Activity towards Cancer.Cancers (Basel). 2021 Jun 29;13(13):3270. doi: 10.3390/cancers13133270. Cancers (Basel). 2021. PMID: 34210001 Free PMC article. Review.
-
Nuclear Mechanisms Involved in Endocrine Resistance.Front Oncol. 2021 Sep 15;11:736597. doi: 10.3389/fonc.2021.736597. eCollection 2021. Front Oncol. 2021. PMID: 34604071 Free PMC article. Review.
References
-
- ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489:57–74. - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical